Acknowledgement
We thank the physicians who referred their patients for inclusion in this clinical trial and who reported their followup data. We are grateful to Mr. Yih-Hwen Huang (Master of Science, Department of Nuclear Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine) for his technical support.
References
- Zhang J, Chen H, Ma Y, Xiao Y, Niu N, Lin W, et al. Characterizing IgG4-related disease with (18)F-FDG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging 2014;41:1624-1634 https://doi.org/10.1007/s00259-014-2729-3
- Cheng MF, Guo YL, Yen RF, Chen YC, Ko CL, Tien YW, et al. Clinical utility of FDG PET/CT in patients with autoimmune pancreatitis: a case-control study. Sci Rep 2018;8:3651
- Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging 2007;34:2088-2095 https://doi.org/10.1007/s00259-007-0562-7
- Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, et al. IgG4-related disease: Clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 2015;67:2466-2475 https://doi.org/10.1002/art.39205
- Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015;74:1171-1177 https://doi.org/10.1136/annrheumdis-2014-206605
- Ito T, Nishimori I, Inoue N, Kawabe K, Gibo J, Arita Y, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol 2007;42 Suppl 18:50-58 https://doi.org/10.1007/s00535-007-2051-y
- Lee HW, Moon SH, Kim MH, Cho DH, Jun JH, Nam K, et al. Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. J Gastroenterol 2018;53:967-977 https://doi.org/10.1007/s00535-018-1434-6
- Park DH, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, et al. Substitution of aspartic acid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis. Gastroenterology 2008;134:440-446 https://doi.org/10.1053/j.gastro.2007.11.023
- Stone JH, Brito-Zeron P, Bosch X, Ramos-Casals M. Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc 2015;90:927-939 https://doi.org/10.1016/j.mayocp.2015.03.020
- Yan J, Chu-Shern JL, Loi HY, Khor LK, Sinha AK, Quek ST, et al. Impact of image reconstruction settings on texture features in (18)F-FDG PET. J Nucl Med 2015;56:1667-1673 https://doi.org/10.2967/jnumed.115.156927
- Berti A, Della-Torre E, Gallivanone F, Canevari C, Milani R, Lanzillotta M, et al. Quantitative measurement of (18) F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology (Oxford) 2017;56:2084-2092 https://doi.org/10.1093/rheumatology/kex234
- Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67:1688-1699 https://doi.org/10.1002/art.39132
- Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013;62:1771-1776 https://doi.org/10.1136/gutjnl-2012-303617
- Park SW, Chung JB, Otsuki M, Kim MH, Lim JH, Kawa S, et al. Conference report: Korea-Japan symposium on autoimmune pancreatitis. Gut Liver 2008;2:81-87 https://doi.org/10.5009/gnl.2008.2.2.81
- Ghazale AH, Chari ST, Vege SS. Update on the diagnosis and treatment of autoimmune pancreatitis. Curr Gastroenterol Rep 2008;10:115-121 https://doi.org/10.1007/s11894-008-0031-x
- Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, et al. Presentation and management of posttreatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009;7:1089-1096 https://doi.org/10.1016/j.cgh.2009.03.021
- Peng Y, Li JQ, Zhang PP, Zhang X, Peng LY, Chen H, et al. Clinical outcomes and predictive relapse factors of IgG4- related disease following treatment: a long-term cohort study. J Intern Med 2019;286:542-552 https://doi.org/10.1111/joim.12942
- Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009;58:1504-1507 https://doi.org/10.1136/gut.2008.172908
- Miki M, Fujimori N, Oono T, Kawabe K, Ohno A, Matsumoto K, et al. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: a single-center retrospective study of 115 patients. J Dig Dis 2019;20:152-158 https://doi.org/10.1111/1751-2980.12708
- Kubota K, Kamisawa T, Okazaki K, Kawa S, Hirano K, Hirooka Y, et al. Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients. J Gastroenterol 2017;52:955-964 https://doi.org/10.1007/s00535-016-1302-1
- Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009;104:2295-2306 https://doi.org/10.1038/ajg.2009.325
- Culver EL, Sadler R, Simpson D, Cargill T, Makuch M, Bateman AC, et al. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am J Gastroenterol 2016;111:733-743 https://doi.org/10.1038/ajg.2016.40
- Parghane RV, Basu S. Pet-CTbased quantitative parameters for assessment of treatment response and disease activity in cancer and noncancerous disorders. PET Clin 2022;17:465-478 https://doi.org/10.1016/j.cpet.2022.03.006
- Sarikaya I, Sarikaya A. Assessing PET parameters in oncologic 18F-FDG studies. J Nucl Med Technol 2020;48:278-282 https://doi.org/10.2967/jnmt.119.236109
- Nakatsuka Y, Handa T, Nakamoto Y, Nobashi T, Yoshihuji H, Tanizawa K, et al. Total lesion glycolysis as an IgG4-related disease activity marker. Mod Rheumatol 2015;25:579-584 https://doi.org/10.3109/14397595.2014.990674
- Ebbo M, Grados A, Guedj E, Gobert D, Colavolpe C, Zaidan M, et al. Usefulness of 2-[18f]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study. Arthritis Care Res (Hoboken) 2014;66:86-96 https://doi.org/10.1002/acr.22058
- Kostakoglu L, Chauvie S. Metabolic tumor volume metrics in lymphoma. Semin Nucl Med 2018;48:50-66 https://doi.org/10.1053/j.semnuclmed.2017.09.005